Key Points
- CEO Kevin McNamara sold 2,000 shares on May 1 at an average price of $421.13 for $842,260, reducing his stake by 2.17% to 90,219 shares (≈$38.0M).
- Chemed beat quarterly EPS expectations with $5.65 (vs. $5.30 est.) while revenue of $657.5M slightly missed estimates, and management set FY2026 guidance of $24.00–$24.75 EPS versus analyst consensus of about 22.3.
- The company pays a $0.60 quarterly dividend ($2.40 annually, ~0.6% yield), has a market cap of $5.65B and a P/E of 23.2, and carries mixed analyst ratings with an average target of $501.50.
Chemed Corporation (NYSE:CHE - Get Free Report) CEO Kevin Mcnamara sold 2,000 shares of the company's stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $421.13, for a total value of $842,260.00. Following the transaction, the chief executive officer directly owned 90,219 shares in the company, valued at approximately $37,993,927.47. This trade represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Chemed Trading Up 0.9%
Shares of Chemed stock opened at $426.05 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.83 and a current ratio of 0.85. Chemed Corporation has a 52 week low of $365.20 and a 52 week high of $583.96. The stock has a 50 day moving average price of $399.29 and a two-hundred day moving average price of $425.94. The stock has a market capitalization of $5.65 billion, a PE ratio of 23.22, a price-to-earnings-growth ratio of 1.58 and a beta of 0.54.
Chemed (NYSE:CHE - Get Free Report) last issued its earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share for the quarter, topping analysts' consensus estimates of $5.30 by $0.35. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The company had revenue of $657.51 million for the quarter, compared to analyst estimates of $659.22 million. During the same period in the prior year, the firm earned $5.63 earnings per share. Chemed's revenue for the quarter was up 1.6% on a year-over-year basis. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, equities analysts anticipate that Chemed Corporation will post 22.3 earnings per share for the current fiscal year.
Chemed Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 13th. Shareholders of record on Monday, February 23rd were issued a dividend of $0.60 per share. The ex-dividend date was Monday, February 23rd. This represents a $2.40 annualized dividend and a yield of 0.6%. Chemed's dividend payout ratio is presently 13.08%.
Analysts Set New Price Targets
CHE has been the subject of several recent research reports. Wall Street Zen raised shares of Chemed from a "hold" rating to a "buy" rating in a research report on Saturday. Weiss Ratings raised shares of Chemed from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, April 29th. Jefferies Financial Group downgraded Chemed from a "buy" rating to a "hold" rating in a research note on Thursday, January 22nd. Zacks Research raised Chemed from a "strong sell" rating to a "hold" rating in a report on Monday, April 27th. Finally, Royal Bank Of Canada increased their price objective on Chemed from $422.00 to $436.00 and gave the stock a "sector perform" rating in a research note on Monday, April 27th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $501.50.
Get Our Latest Analysis on CHE
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its position in Chemed by 3.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 734 shares of the company's stock worth $314,000 after purchasing an additional 22 shares in the last quarter. WCM Investment Management LLC lifted its position in shares of Chemed by 3.8% during the 3rd quarter. WCM Investment Management LLC now owns 661 shares of the company's stock worth $299,000 after buying an additional 24 shares in the last quarter. Eukles Asset Management lifted its position in shares of Chemed by 0.4% during the 3rd quarter. Eukles Asset Management now owns 6,031 shares of the company's stock worth $2,700,000 after buying an additional 24 shares in the last quarter. Cim LLC boosted its stake in shares of Chemed by 1.1% in the 3rd quarter. Cim LLC now owns 2,139 shares of the company's stock worth $958,000 after buying an additional 24 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Chemed by 71.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 60 shares of the company's stock worth $27,000 after buying an additional 25 shares during the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.
Chemed Company Profile
(
Get Free Report)
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
